Cedar Pollen Allergy - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cedar Pollen Allergy - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Cedar Pollen Allergy - Pipeline Review, H2 2015', provides an overview of the Cedar Pollen Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cedar Pollen Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Cedar Pollen Allergy - Overview 7
Pipeline Products for Cedar Pollen Allergy - Comparative Analysis 8
Cedar Pollen Allergy - Therapeutics under Development by Companies 9
Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 10
Cedar Pollen Allergy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Cedar Pollen Allergy - Products under Development by Companies 13
Cedar Pollen Allergy - Products under Investigation by Universities/Institutes 14
Cedar Pollen Allergy - Companies Involved in Therapeutics Development 15
Anergis SA 15
Biomay AG 16
Circassia Pharmaceuticals Plc 17
Immunomic Therapeutics, Inc. 18
Japan Tobacco Inc. 19
REGiMMUNE Corporation 20
Cedar Pollen Allergy - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AllerJ - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ASP-4070 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Drugs for Cedar Pollen Allergy - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
japanese cedar hypoallergenic vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
JCC-LAMP-Vax - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MC-LAMP-Vax - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RGI-1001 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TO-206 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Vaccine for Cedar Pollen Allergy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Vaccine for Japanese Cedar Pollen Allergy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cedar Pollen Allergy - Recent Pipeline Updates 38
Cedar Pollen Allergy - Dormant Projects 40
Cedar Pollen Allergy - Product Development Milestones 41
Featured News & Press Releases 41
Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference 41
Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting 41
Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study To Treat Japanese Red Cedar Allergy 42
Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables

Number of Products under Development for Cedar Pollen Allergy, H2 2015 7
Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Cedar Pollen Allergy - Pipeline by Anergis SA, H2 2015 15
Cedar Pollen Allergy - Pipeline by Biomay AG, H2 2015 16
Cedar Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2015 17
Cedar Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2015 18
Cedar Pollen Allergy - Pipeline by Japan Tobacco Inc., H2 2015 19
Cedar Pollen Allergy - Pipeline by REGiMMUNE Corporation, H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Route of Administration, H2 2015 24
Number of Products by Stage and Molecule Type, H2 2015 26
Cedar Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2015 38
Cedar Pollen Allergy - Dormant Projects, H2 2015 40